| Literature DB >> 31275371 |
Mujahed I Mustafa1,2, Tebyan A Abdelhameed2, Fatima A Abdelrhman2, Soada A Osman2, Mohamed A Hassan2.
Abstract
BACKGROUND: Familial Mediterranean Fever (FMF) is the most common autoinflammatory disease (AID) affecting mainly the ethnic groups originating from Mediterranean basin. We aimed to identify the pathogenic SNPs in MEFV by computational analysis software.Entities:
Year: 2019 PMID: 31275371 PMCID: PMC6582883 DOI: 10.1155/2019/1651587
Source DB: PubMed Journal: Adv Bioinformatics ISSN: 1687-8027
Damaging or deleterious effect nsSNPs associated variations predicted by various softwares.
|
|
|
|
|
| ||||
|---|---|---|---|---|---|---|---|---|
| prediction | Score | Prediction | score | Score | Prediction (cutoff= -2.5) | prediction | score | |
| S749Y | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -3.116 | Deleterious | effect | 64 |
| F743S | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -5.563 | Deleterious | effect | 68 |
| Y741C | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -6.035 | Deleterious | effect | 77 |
| F731V | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -5.159 | Deleterious | effect | 81 |
| I720T | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -3.639 | Deleterious | effect | 58 |
| L709R | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -4.311 | Deleterious | effect | 77 |
| V691G | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -4.667 | Deleterious | effect | 66 |
| W689R | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -10.132 | Deleterious | effect | 89 |
| G668R | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -6.287 | Deleterious | effect | 92 |
| V659F | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -3.811 | Deleterious | effect | 64 |
| F636C | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -6.49 | Deleterious | effect | 79 |
| R461W | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -5.456 | Deleterious | effect | 68 |
| H407Q | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -7.335 | Deleterious | effect | 41 |
| H407R | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -7.332 | Deleterious | effect | 51 |
| H404R | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -7.349 | Deleterious | effect | 75 |
| C398Y | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -10.314 | Deleterious | effect | 51 |
| C395Y | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -10.262 | Deleterious | effect | 19 |
| C395F | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -10.315 | Deleterious | effect | 27 |
| C395R | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -11.074 | Deleterious | effect | 27 |
| H378Q | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -5.886 | Deleterious | effect | 38 |
| H378Y | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -4.884 | Deleterious | effect | 45 |
| C375R | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -8.429 | Deleterious | effect | 66 |
| L86P | DAMAGING | 0 | PROBABLY DAMAGING | 1.000 | -4.1 | Deleterious | effect | 19 |
Disease effect nsSNPs associated variations predicted by various softwares.
|
| SNP&GO | PHD-SNP | P-Mut | |||||
|---|---|---|---|---|---|---|---|---|
| Prediction | RI | Probability | Prediction | RI | Score | Score | Prediction | |
| S749Y | Disease | 1 | 0.573 | Disease | 3 | 0.649 | 0.67 (85%) | Disease |
| F743S | Disease | 2 | 0.617 | Disease | 4 | 0.696 | 0.82 (90%) | Disease |
| Y741C | Disease | 6 | 0.797 | Disease | 7 | 0.869 | 0.61 (83%) | Disease |
| F731V | Disease | 6 | 0.79 | Disease | 8 | 0.899 | 0.93 (94%) | Disease |
| I720T | Disease | 6 | 0.811 | Disease | 5 | 0.769 | 0.81 (89%) | Disease |
| L709R | Disease | 3 | 0.672 | Disease | 4 | 0.695 | 0.66 (85%) | Disease |
| V691G | Disease | 1 | 0.55 | Disease | 3 | 0.675 | 0.92 (93%) | Disease |
| W689R | Disease | 7 | 0.841 | Disease | 8 | 0.924 | 0.93 (94%) | Disease |
| G668R | Disease | 6 | 0.778 | Disease | 7 | 0.84 | 0.93 (94%) | Disease |
| V659F | Disease | 6 | 0.805 | Disease | 7 | 0.84 | 0.82 (90%) | Disease |
| F636C | Disease | 6 | 0.809 | Disease | 7 | 0.86 | 0.60 (82%) | Disease |
| R461W | Disease | 3 | 0.644 | Disease | 1 | 0.572 | 0.63 (84%) | Disease |
| H407Q | Disease | 6 | 0.788 | Disease | 4 | 0.705 | 0.79 (89%) | Disease |
| H407R | Disease | 5 | 0.769 | Disease | 3 | 0.673 | 0.86 (91%) | Disease |
| H404R | Disease | 5 | 0.744 | Disease | 5 | 0.734 | 0.80 (89%) | Disease |
| C398Y | Disease | 7 | 0.864 | Disease | 8 | 0.912 | 0.86 (91%) | Disease |
| C395Y | Disease | 7 | 0.864 | Disease | 8 | 0.912 | 0.91 (93%) | Disease |
| C395F | Disease | 7 | 0.859 | Disease | 8 | 0.914 | 0.92 (94%) | Disease |
| C395R | Disease | 7 | 0.842 | Disease | 8 | 0.892 | 0.92 (94%) | Disease |
| H378Q | Disease | 4 | 0.714 | Disease | 4 | 0.698 | 0.88 (92%) | Disease |
| H378Y | Disease | 5 | 0.732 | Disease | 5 | 0.728 | 0.80 (89%) | Disease |
| C375R | Disease | 6 | 0.784 | Disease | 6 | 0.822 | 0.92 (94%) | Disease |
| L86P | Disease | 5 | 0.729 | Disease | 6 | 0.801 | 0.51 (79%) | Disease |
Stability analysis predicted by I-Mutant version 3.0 (also show the 23 novel mutations).
|
| SVM2 Prediction Effect | RI | DDG Value Prediction |
|---|---|---|---|
| S749Y | Decrease | 0 | -0.2 |
| F743S | Decrease | 6 | -1.16 |
| Y741C | Decrease | 8 | -2.5 |
| F731V | Decrease | 6 | -1.52 |
| I720T | Decrease | 4 | -0.92 |
| L709R | Decrease | 3 | -0.56 |
| V691G | Decrease | 7 | -1.25 |
| W689R | Decrease | 7 | -0.73 |
| G668R | Decrease | 4 | -0.37 |
| V659F | Decrease | 2 | -0.19 |
| F636C | Decrease | 8 | -1.28 |
| R461W | Increase | 1 | -0.01 |
| H407Q | Decrease | 8 | -1.48 |
| H407R | Decrease | 5 | -1.1 |
| H404R | Decrease | 1 | -0.06 |
| C398Y | Decrease | 2 | -0.09 |
| C395Y | Increase | 4 | 0.26 |
| C395F | Increase | 1 | 0.04 |
| C395R | Increase | 4 | 0.13 |
| H378Q | Decrease | 4 | -0.68 |
| H378Y | Decrease | 3 | -0.26 |
| C375R | Increase | 2 | -0.01 |
| L86P | Decrease | 2 | -0.56 |
The MEFV gene functions and its appearance in network and genome.
| Function | FDR | Genes in network | Genes in genome |
|---|---|---|---|
| nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway | 1.42E-07 | 6 | 47 |
| regulation of interleukin-1 beta production | 0.000129 | 4 | 26 |
| interleukin-1 beta production | 0.000129 | 4 | 30 |
| regulation of interleukin-1 production | 0.000129 | 4 | 30 |
| interleukin-1 production | 0.000196 | 4 | 35 |
| intracellular receptor signaling pathway | 0.000201 | 6 | 207 |
| positive regulation of cysteine-type endopeptidase activity | 0.010438 | 4 | 101 |
| positive regulation of endopeptidase activity | 0.010663 | 4 | 105 |
| positive regulation of peptidase activity | 0.011 | 4 | 109 |
| inflammatory response | 0.018246 | 5 | 283 |
| regulation of chemokine production | 0.018246 | 3 | 39 |
| chemokine production | 0.022338 | 3 | 44 |
| regulation of cysteine-type endopeptidase activity | 0.033238 | 4 | 160 |
| tumor necrosis factor production | 0.033238 | 3 | 54 |
| regulation of tumor necrosis factor production | 0.033238 | 3 | 54 |
| tumor necrosis factor superfamily cytokine production | 0.0407 | 3 | 59 |
| regulation of I-kappaB kinase/NF-kappaB signaling | 0.046902 | 4 | 185 |
| I-kappaB kinase/NF-kappaB signaling | 0.057722 | 4 | 198 |
| positive regulation of cytokine production | 0.065004 | 4 | 207 |
| positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 0.099763 | 3 | 93 |
| positive regulation of interleukin-1 beta secretion | 0.099763 | 2 | 15 |
| defense response to Gram-negative bacterium | 0.099763 | 2 | 16 |
| cysteine-type endopeptidase activator activity involved in apoptotic process | 0.099763 | 2 | 17 |
| regulation of endopeptidase activity | 0.099763 | 4 | 251 |
| glycosaminoglycan binding | 0.099763 | 3 | 88 |
| regulation of extrinsic apoptotic signaling pathway | 0.099763 | 3 | 92 |
| regulation of peptidase activity | 0.099763 | 4 | 258 |
| positive regulation of interleukin-1 secretion | 0.099763 | 2 | 16 |
| regulation of interleukin-1 beta secretion | 0.099763 | 2 | 17 |
∗FDR: false discovery rate is greater than or equal to the probability that this is a false positive.
The gene coexpression, shared domain, and interaction with MEFV gene network.
| Gene 1 | Gene 2 | Weight | Network group |
|---|---|---|---|
| PF4 | CEBPB | 0.01083 | Co-expression |
| NLRP14 | MEFV | 0.014663 | Co-expression |
| EPX | PADI4 | 0.01094 | Co-expression |
| CASP1 | PYCARD | 0.012291 | Co-expression |
| TINAGL1 | MEFV | 0.021529 | Co-expression |
| ZNF747 | MEFV | 0.032075 | Co-expression |
| ZNF747 | TINAGL1 | 0.01915 | Co-expression |
| EPX | MEFV | 0.019982 | Co-expression |
| EPX | ZNF747 | 0.01848 | Co-expression |
| MRPL44 | MEFV | 0.02576 | Co-expression |
| RPL27A | MEFV | 0.023047 | Co-expression |
| TCTN2 | MEFV | 0.02049 | Co-expression |
| TCTN2 | ZNF747 | 0.021219 | Co-expression |
| TCTN2 | RPL27A | 0.019574 | Co-expression |
| ZNF528 | RPL27A | 0.021843 | Co-expression |
| ZNF528 | TCTN2 | 0.020287 | Co-expression |
| PF4 | TINAGL1 | 0.018596 | Co-expression |
| PF4 | EPX | 0.016477 | Co-expression |
| CASP1 | PYCARD | 0.005924 | Co-expression |
| NLRP3 | CEBPB | 0.01342 | Co-expression |
| CASP1 | PYCARD | 0.005896 | Co-expression |
| AZU1 | MEFV | 0.01109 | Co-expression |
| MAP1LC3C | NLRP14 | 0.011062 | Co-expression |
| PADI4 | MEFV | 0.003094 | Co-expression |
| AZU1 | MEFV | 0.003152 | Co-expression |
| AZU1 | PADI4 | 0.004853 | Co-expression |
| ZNF747 | MEFV | 0.004908 | Co-expression |
| PADI4 | MEFV | 0.023362 | Co-expression |
| AZU1 | MEFV | 0.012616 | Co-expression |
| AZU1 | PADI4 | 0.014322 | Co-expression |
| NLRP14 | MEFV | 0.01623 | Co-expression |
| EPX | PADI4 | 0.01024 | Co-expression |
| EPX | AZU1 | 0.007038 | Co-expression |
| ZNF528 | MEFV | 0.039375 | Co-expression |
| PF4 | MEFV | 0.017902 | Co-expression |
| PF4 | AZU1 | 0.012247 | Co-expression |
| PF4 | EPX | 0.007715 | Co-expression |
| TINAGL1 | MEFV | 0.027084 | Co-expression |
| MRPL44 | MEFV | 0.011927 | Co-expression |
| TCTN2 | MEFV | 0.014192 | Co-expression |
| TCTN2 | TINAGL1 | 0.014867 | Co-expression |
| TCTN2 | ZNF747 | 0.010889 | Co-expression |
| TCTN2 | MAP1LC3C | 0.006994 | Co-expression |
| TCTN2 | MRPL44 | 0.010528 | Co-expression |
| ZNF528 | TCTN2 | 0.012167 | Co-expression |
| RPL27A | MEFV | 0.016846 | Co-expression |
| TCTN2 | RPL27A | 0.018021 | Co-expression |
| CASP1 | PSTPIP1 | 0.009518 | Co-expression |
| EPX | AZU1 | 0.01909 | Co-localization |
| PADI4 | MEFV | 0.012301 | Co-localization |
| PADI4 | PSTPIP1 | 0.008748 | Co-localization |
| AZU1 | MEFV | 0.011852 | Co-localization |
| AZU1 | PSTPIP1 | 0.008052 | Co-localization |
| AZU1 | PADI4 | 0.006025 | Co-localization |
| EPX | MEFV | 0.011933 | Co-localization |
| EPX | PSTPIP1 | 0.008374 | Co-localization |
| EPX | PADI4 | 0.006323 | Co-localization |
| EPX | AZU1 | 0.006061 | Co-localization |
| FBXO9 | MEFV | 0.022287 | Co-localization |
| FBXO9 | PADI4 | 0.009957 | Co-localization |
| FBXO9 | AZU1 | 0.009656 | Co-localization |
| FBXO9 | EPX | 0.009948 | Co-localization |
| PF4 | MEFV | 0.012063 | Co-localization |
| PF4 | PSTPIP1 | 0.007583 | Co-localization |
| PF4 | PADI4 | 0.005603 | Co-localization |
| PF4 | AZU1 | 0.005356 | Co-localization |
| PF4 | EPX | 0.005651 | Co-localization |
| PF4 | FBXO9 | 0.009449 | Co-localization |
| CEBPB | MEFV | 0.159581 | Pathway |
| RELA | MEFV | 0.078321 | Pathway |
| PSTPIP1 | MEFV | 0.953023 | Pathway |
| PYCARD | MEFV | 0.037199 | Pathway |
| CASP1 | PYCARD | 0.037199 | Pathway |
| CASP1 | MEFV | 0.469715 | Physical Interactions |
| NLRP3 | PYCARD | 0.570819 | Physical Interactions |
| PYCARD | MEFV | 0.03673 | Physical Interactions |
| PYCARD | PSTPIP1 | 0.028273 | Physical Interactions |
| CASP1 | PYCARD | 0.017772 | Physical Interactions |
| CASP1 | CEBPB | 0.010941 | Physical Interactions |
| RELA | CEBPB | 0.00247 | Physical Interactions |
| COG5 | MEFV | 0.211887 | Physical Interactions |
| NLRP3 | MEFV | 0.111467 | Physical Interactions |
| MAP1LC3C | MEFV | 0.104412 | Physical Interactions |
| PYCARD | MEFV | 0.292858 | Physical Interactions |
| NLRP3 | PYCARD | 0.189095 | Physical Interactions |
| PSTPIP1 | MEFV | 0.260595 | Physical Interactions |
| PYCARD | MEFV | 0.204673 | Physical Interactions |
| CASP1 | PYCARD | 0.042335 | Physical Interactions |
| RELA | CEBPB | 0.007591 | Physical Interactions |
| COG5 | MEFV | 0.387501 | Physical Interactions |
| NLRP3 | PYCARD | 0.304828 | Physical Interactions |
| NLRP3 | PYCARD | 1 | Predicted |
| PYCARD | MEFV | 0.455503 | Predicted |
| CASP1 | PYCARD | 0.043769 | Predicted |
| RELA | CEBPB | 0.024601 | Predicted |
| NLRP3 | PYCARD | 0.25852 | Predicted |
| CASP1 | CEBPB | 0.445416 | Predicted |
| CASP1 | CEBPB | 0.707107 | Predicted |
| PYCARD | MEFV | 0.00952 | Shared protein domains |
| CASP1 | PYCARD | 0.013543 | Shared protein domains |
| NLRP3 | MEFV | 0.009339 | Shared protein domains |
| NLRP3 | PYCARD | 0.018527 | Shared protein domains |
| NLRP14 | MEFV | 0.009512 | Shared protein domains |
| NLRP14 | PYCARD | 0.018871 | Shared protein domains |
| NLRP14 | NLRP3 | 0.036989 | Shared protein domains |
| ZNF528 | ZNF747 | 0.002699 | Shared protein domains |
| PYCARD | MEFV | 0.011528 | Shared protein domains |
| CASP1 | PYCARD | 0.031451 | Shared protein domains |
| NLRP3 | MEFV | 0.009427 | Shared protein domains |
| NLRP3 | PYCARD | 0.015448 | Shared protein domains |
| NLRP14 | MEFV | 0.009815 | Shared protein domains |
| NLRP14 | PYCARD | 0.016085 | Shared protein domains |
| NLRP14 | NLRP3 | 0.019774 | Shared protein domains |
| ZNF528 | ZNF747 | 0.002759 | Shared protein domains |
Figure 1Diagrammatic representation of MEFV gene in silico work flow.
Figure 2Alignments of 10 amino acid sequences of MEFV demonstrating that the residues predicted to be mutated in our band (indicated by red arrow) are evolutionarily conserved across species. Sequences Alignment was done by BioEdit (v7.2.5).
Figure 3(L86P): change in the amino acid Leucine (green box) into Proline (red box) at position 86.
Figure 4(C375R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 375.
Figure 5(H378Y): change in the amino acid Histidine (green box) into Tyrosine (red box) at position 378.
Figure 6(H378Q): change in the amino acid Histidine (green box) into Glutamine (red box) at position 378.
Figure 7(C395R): change in the amino acid Cysteine (green box) into Arginine (red box) at position 395.
Figure 8(C395F): change in the amino acid Cysteine (green box) into Phenylalanine (red box) at position 395.
Figure 9(C395Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 395.
Figure 10(C398Y): change in the amino acid Cysteine (green box) into Tyrosine (red box) at position 398.
Figure 11(H404R): change in the amino acid Histidine (green box) into Arginine (red box) at position 404.
Figure 12(H407R): change in the amino acid Histidine (green box) into Arginine (red box) at position 407.
Figure 13(H407Q): change in the amino acid Histidine (green box) into Glutamine (red box) at position 407.
Figure 14(R461W): change in the amino acid Arginine (green box) into Tryptophan (red box) at position 461.
Figure 15(F636C): change in the amino acid Phenylalanine (green box) into Cysteine (red box) at position 636.
Figure 16(V659F): change in the amino acid Valine (green box) into Phenylalanine (red box) at position 636.
Figure 17(G668R): change in the amino acid Glycine (green box) into Arginine (red box) at position 668.
Figure 18(W689R): change in the amino acid Tryptophan (green box) into Arginine (red box) at position 689.
Figure 19(V691G): change in the amino acid Valine (green box) into Glycine (red box) at position 691.
Figure 20(L709R): change in the amino acid Leucine (green box) into Arginine (red box) at position 709.
Figure 21(I720T): change in the amino acid Isoleucine (green box) into Threonine (red box) at position 720.
Figure 22(F731V): change in the amino acid Phenylalanine (green box) into Valine (red box) at position 731.
Figure 23(Y741C): change in the amino acid Tyrosine (green box) into Cysteine (red box) at position 731.
Figure 24(F743S): change in the amino acid Phenylalanine (green box) into Serine (red box) at position 743.
Figure 25(S749Y): change in the amino acid Serine (green box) into Tyrosine (red box) at position 749.
Figure 26Interaction between MEFV and its related genes.